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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYHere, we asked whether we could identify pharmacological agents that enhance endogenous stem cell function to promote skin repair,
focusing on skin-derived precursors (SKPs), a dermal precursor cell population. Libraries of compounds already used in humans were
screened for their ability to enhance the self-renewal of human and rodent SKPs. We identified and validated five such compounds,
and showed that two of them, alprostadil and trimebutine maleate, enhanced the repair of full thickness skin wounds in middle-aged
mice. Moreover, SKPs isolated from drug-treated skin displayed long-term increases in self-renewal when cultured in basal growth
medium without drugs. Both alprostadil and trimebutine maleate likely mediated increases in SKP self-renewal by moderate hyperacti-
vation of the MEK-ERK pathway. These findings identify candidates for potential clinical use in human skin repair, and provide support
for the idea that pharmacological activation of endogenous tissue precursors represents a viable therapeutic strategy.INTRODUCTION
Advances in adult tissue stem cell biology have led to the
idea that pharmacological activation of resident stem cells
might represent a therapeutic strategy for tissue repair
(Miller and Kaplan, 2012). Indeed, pharmacological candi-
dates that regulate tissue stem cells have been identified
including, for example, metformin for neural precursors
(Wang et al., 2012; Dadwal et al., 2015) and StemRegenin 1
for primary human hematopoietic stem cells (Boitano
et al., 2010). Here, we asked whether this is a viable strategy
for skin repair. Skin is a complex tissue with many endoge-
nous tissue stem cells. These include epidermal stem cells
(Hsu et al., 2014) and a population of dermal stem cells
called skin-derived precursors (SKPs) (Toma et al., 2001,
2005). Cultured SKPs clonally generatemesenchymal prog-
eny like dermal fibroblasts and adipocytes, and peripheral
neural progeny like Schwann cells, consistent with the
finding that they derive from both neural crest and meso-
dermal origins (Fernandes et al., 2004; McKenzie et al.,
2006; Jinno et al., 2010; Krause et al., 2014), like the dermis
itself. With regard to their in vivo function, cultured SKPs
can clonally reconstitute the dermis and induce hair follicle
morphogenesis (Biernaskie et al., 2009), suggesting key74 Stem Cell Reports j Vol. 6 j 74–84 j January 12, 2016 j ª2016 The Authorroles for the endogenous precursors in dermal mainte-
nance and hair follicle biology.
Here, we have tested the idea that increasing the number
and/or self-renewal of endogenous SKPs would enhance
skin repair. To do so, we screened libraries of compounds
that are used clinically in humans, looking for drugs that
enhance SKP self-renewal. We identified two compounds,
alprostadil and trimebutine maleate (TM), that increased
SKP self-renewal, likely by activating the MEK-ERK
pathway. Both compounds enhanced wound healing
when applied topically. These findings provide proof of
principle for the idea that compounds that regulate SKPs
in culture have therapeutic efficacy in vivo, and identify
potential drug candidates that can be repositioned for use
in humans.RESULTS
Screens to Identify Compounds that Enhance Human
and Rodent SKP Self-Renewal and Proliferation
We performed high-throughput proliferation screens using
primary human foreskin SKPs and neonatal rat dorsal SKPs
grown as spheres in serum-free growthmedium containings
Figure 1. Identification of Compounds that Enhance Self-Renewal and Proliferation of Cultured SKPs
(A–C) Number of SKP spheres generated from secondary human SKPs grown for 7 days in varying concentrations of alprostadil (Alp) (A) or
TM (B) or in 100 nM alprostadil, TM, kaempferol (Kae), MG-624, or pramoxine (Pram) (C). In (C) numbers are expressed relative to DMSO
alone.
(D–F) Number of SKP spheres generated from secondary neonatal rat SKPs grown for 7 days in 100 nM of each of the five drugs (D), or in
varying concentrations of alprostadil (E) or TM (F).
(G and H) Number (G) and size (H) of rat SKP spheres generated over 7 days in 100 nM alprostadil, TM, or both.
(I) Number of rat SKP spheres generated in 14-day clonal methylcellulose assays with 100 nM alprostadil, TM, or latanoprost (Latan).
(legend continued on next page)
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40 ng/ml fibroblast growth factor 2 (FGF2) and 20 ng/ml
epidermal growth factor (EGF). This study was approved
by the Hospital for Sick Children Animal Care Committee
in accordance with CCAC guidelines, and for human tis-
sues and cells, with the approval of the Research Ethics
Board of the Hospital for Sick Children.We chose 3,000 hu-
man and 5,000 rat SKP cells per well as optimal cell
numbers by robotically plating cells in 96-well plates, add-
ing alamarBlue at 30 hr, and assessing its reduction 24 hr
later as a measure of cell metabolic activity (Figure S1A)
(Smith et al., 2010).We then performed two sets of screens.
In one, spheres from four independent human SKP lines
(Smith et al., 2010) were dissociated and treated with the
Prestwick library of 1,120 compounds (primarily marketed
drugs), and the LOPAC-Sigma library of 1,280 compounds
with proven biological activity at 1 or 5 mM. In the second,
rat or human SKPs were treated with the NIH Clinical
Collection library of 446 highly drug-like compounds
with known human safety profiles.
Hits were defined as (1) compounds with signals
(B scores) shifted at least three SDs (99.73% confidence in-
terval) from the mean of the general sample population
(Figures S1B and S1C), or (2) compounds with a 20% or
more increase in alamarBlue values relative to controls in
at least three different human SKP lines. For secondary
screens, we dissociated human SKPs from at least three in-
dependent lines, plated them in growth medium, added
drugs on days 1 and 4, and on day 7 quantified spheres as
an index of self-renewal. This analysis (Figures 1A and 1B;
Figures S1D–S1F) confirmed five of the potential hits: al-
prostadil (prostaglandin E1 [PGE1]), used for erectile
dysfunction (Hanchanale and Eardley, 2014); TM, a weak
opioid receptor agonist and spasmolytic (Delvaux and
Wingate, 1997); the natural flavonoid kaempferol (Cal-
dero´n-Montan˜o et al., 2011); MG-624, an a7-nicotinic
acetylcholine receptor antagonist used for postoperative
vomiting (Gotti et al., 1998); and pramoxine, a local anes-
thetic (Fisher, 1998). All compounds have been used in hu-
mans, and all but MG-624 have been used topically. Three
compounds, alprostadil, TM, and kaempferol, enhanced
sphere number at doses as low as 1–10 nM (Figures 1A
and 1B; Figure S1D), while others had effects at higher con-
centrations (Figures S1E and S1F). None of the compounds
had toxic effects at concentrations up to 1 mM except for(J and K) Secondary rat SKP spheres were grown for 4 days, and 100
spheres immunostained for Ki67 (top) and counterstained with DAPI t
cells. Scale bar represents 100 mm.
(L) NIH 3T3 cells were treated for 24 hr with 100 nM alprostadil or
determined. N.S., not significant.
In all panels, results were pooled from 3 to 4 independent experimen
Error bars indicate SEM, and in all cases *p < 0.05, **p < 0.01, ***p < 0
also Figure S1.
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100 nM, all the drugs promoted sphere formation to
approximately the same extent (Figure 1C). Similar results
were obtained in secondary sphere formation assays with
neonatal rat SKPs (Figure 1D).
We chose alprostadil and TM formore detailed character-
ization, since (1) they were efficacious in secondary
screens, (2) they are used topically in humans, and (3)
SKPs express the mRNAs encoding the EP(1–4) prostanoid
receptors for alprostadil and the mu and kappa-opioid re-
ceptors for TM (data not shown). Initially, we performed
dose-response curves with rat SKPs. Sphere numbers
increased in a dose-dependent fashion to a maximum at
103–308 nM for alprostadil and 308 nM for TM (Figures
1E and 1F). Second, we added 100 nM of the drugs together
or alone in sphere formation assays. Each drug alone
increased sphere number and size (the latter a surrogate
measure of proliferation), with no further increase with
both (Figures 1G and 1H), suggesting that they might act
via similar mechanisms. Third, we measured self-renewal
using a colony formation assay in which rat SKPs were
plated at clonal density (2.5 cells/ml) inmedium containing
1.6%methylcellulose. For comparison, we also analyzed la-
tanoprost, a prostaglandin (PGF2) that is bioactive in ro-
dent and human skin (Sasaki et al., 2005). Clonal sphere
numbers were significantly increased by all three drugs at
14 days (Figure 1I). Finally, we directly measured prolifera-
tion; rat SKPs were cultured for 3–4 days, treated with drugs
daily for a further 2 days, and immunostained for the pro-
liferation marker Ki67. Both drugs increased Ki67-positive
sphere cells by approximately 60% (Figures 1J and 1K).
These drugs are not general mitogens, since Ki67-positive
NIH 3T3 cells were unaffected in similar assays (Figure 1L).
Thus, alprostadil and TM increase SKP proliferation and
self-renewal.
Alprostadil and TM Enhance Skin Repair in Middle-
Aged Mice
To ask whether alprostadil or TM promoted skin repair, we
performed 6-mmdiameter full thickness punchwounds on
middle-aged (9 months old) mice, as we have previously
described (Johnston et al., 2013), and applied the drugs
daily for 9 days around the injury site, using 100 mM drug
in a propylene glycol-ethanol-water mixture that enablesnM alprostadil or TM was added for two additional days. (J) shows
o show nuclei (bottom). (K) shows the percentage of Ki67-positive
TM, immunostained for Ki67, and the percentage of positive cells
ts with, in the human experiments, 3–4 different human SKP lines.
.001, one-way ANOVA with multiple comparison post hoc tests. See
s
Figure 2. Topical Alprostadil or TM Promotes Skin Repair in Middle-Aged Mice
(A and B) Scatterplots showing wound closure at 7 days (A) and 9 days (B) after injury for 9-month-old mice treated daily with alprostadil
(Alp), TM, or vehicle alone (Control). n = 10 or 14 mice per group, from three independent experiments.
(C–F) H&E-stained sections through the center of the wound bed 9 days after injury (C) were analyzed for wound width (D), epithelial gap
(E), and new dermal tissue (F). n = 18, 14, and 17, vehicle-, alprostadil-, and TM-treated mice total, from three independent experiments.
NE indicates the new epithelium, RD the regenerating dermis, and OW the borders of the wound. Scale bar represents 1 mm.
(legend continued on next page)
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dermal penetration (Tata et al., 1995). Wound closure was
significantly accelerated in drug-treated mice. On day 7,
almost half of the alprostadil- or TM-treatedmicewere fully
healed, as opposed to none of the vehicle-treated controls
(Figure 2A). By day 9, 70%–78% (11 of 14 for alprostadil
and 10 of 14 for TM) of drug-treated mice were healed
compared with 44% (8 of 18) of the vehicle-treated mice
(Figure 2B).
Morphometric analyses of H&E-stained paraffin sections
from the central portion of the wound bed on day 9 (Fig-
ure 2C) confirmed these results. Wound width (Figure 2D)
and epithelial gap (Figure 2E) were both significantly
smaller in alprostadil- or TM-treated mice. Dermal tissue
regeneration was also enhanced, with a thicker layer of
new dermal tissue (Figures 2C and 2F). In alprostadil-
treated mice, this coincided with increased Ki67-positive
proliferating dermal cells at the leading edge of the
newly formed dermis 7 days after injury (Figures 2G and
2H). Treatment with alprostadil or TM also increased
CD31-positive blood vessels in the same region (Figures
2I and 2J).
Topical Treatment of Mouse Skin with Alprostadil or
TM in Vivo Causes Long-Term Enhancement of the
Self-Renewal of SKPs Cultured from Treated Skin in
the Absence of Drugs
These data indicate that alprostadil and TM enhance SKPs
self-renewal in culture and promote skin repair in vivo.
To provide a link between these two activities, we per-
formed punch wounds on 9-month-old mice, treated
them with alprostadil, TM, or vehicle daily for 7 days,
and then cultured SKPs from the regenerating skin without
added drugs. For comparison, we analyzed uninjured mice
following topical drug application for 7 days. The number
and size of secondary SKP spheres were increased when
they were isolated from either injured or uninjured drug-
treated skin (Figures 3A–3D; Figure S2A), indicating that al-
prostadil and TM somehow regulated endogenous dermal
precursors to affect their long-term self-renewal even
when they were isolated and cultured without these drugs.
To ask about the nature of the drug-induced change(s),
we performed transcriptome analysis on the different sec-
ondary SKP sphere populations, isolating RNA from three
independent biological replicates of each and using Affy-
metrix GeneChip Mouse Gene 2.0 ST Arrays. Unbiased hi-(G–J) Sections from the center of the wound bed of mice 7 days afte
counterstained with hematoxylin, and analyzed for the percentage of K
vessels (J) at the leading edge of the regenerating dermis. n = at lea
(G and I) show higher magnification images, with arrows denoting pos
new epidermis, and RD the regenerating dermis. Scale bar represents
Error bars indicate SEM, and in all cases *p < 0.05, **p < 0.01, ***p
except for (E), where comparisons were made by pairwise Student’s t
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of a Euclidean distance matrix of log2 normalized expres-
sion data demonstrated that, while the different biological
replicates for each treatment population clustered together,
the different populations were all highly similar to each
other (Figure 3E). Intriguingly, the clustering also showed
that SKPs from alprostadil- and TM-treated injured skin
were more similar to each other and to those from unin-
jured skin than to SKPs from vehicle-treated injured skin,
potentially reflecting the accelerated wound healing
caused by these two drugs.
The conclusion that these different SKP populationswere
all similar was further supported by differential gene
expression analysis with the limma bioconductor package
(Ritchie et al., 2015). Only 165 and 291 annotated genes
were differentially expressed in SKPs from alprostadil and
TM versus vehicle-treated injured skin, respectively (p <
0.01 for both comparisons) (Figure 3F). These differentially
expressed genes were largely non-overlapping (Tables S1
and S2), with only 21 shared between the alprostadil and
TM groups (Figure S2B). Thus, transcriptionally similar
SKP populations are present from treated or untreated
skin, and somehow the drug treatments enhance their
long-term self-renewal when these SKPs are cultured
in vitro.
Alprostadil and TM Regulate Genes in Cultured SKPs
that Are Associated with Cell Proliferation and the
MAP Kinase Pathway
One potential explanation for the modest gene expression
changes observed in the long-term experiments was the
long lag time between drug exposure and analysis. We
therefore performed acute drug exposure experiments. Pri-
mary rat SKPs were passaged, acutely treated with drugs for
24 hr, and analyzed via microarrays as for the long-term
experiments. This analysis identified 457 and 545 differen-
tially expressed genes in the pairwise comparisons of con-
trol versus alprostadil or TM treatment, respectively (p <
0.01 for both comparisons) (Tables S3 and S4). The changes
were generally of higher magnitude for alprostadil than for
TM (Figure 3G), but more than half of the significantly
changed genes (295) were shared between the two groups
(Figure 3H; Table S5). In addition, of the top 50 differen-
tially expressed genes in the two pairwise comparisons
(defined as highest significance; Table S6 and S7), 23 werer injury were immunostained for Ki67 (G and H) or CD31 (I and J),
i67-positive cells (H) or the relative number of CD31-positive blood
st nine mice per group in (H) and three per group in (J). Insets in
itive cells (black or dark brown). LE indicates the leading edge of the
125 mm.
< 0.001, one-way ANOVA with multiple comparison post hoc tests
tests.
s
Figure 3. Topical Treatment of Mouse Skin with Alprostadil or TM In Vivo Alters the Self-Renewal of SKPs Cultured from the Treated
Skin in the Absence of Drug, and Acute Drug Treatment of Cultured SKPs Causes Changes in Gene Expression
(A–D) Primary SKPs were isolated from 9-month-old mice that had received punch wounds (Inj Skin; A and B) or that had intact skin (Uninj
Skin; C and D) and that were then treated with topical vehicle (Control), alprostadil (Alp), or TM for 7 days. The primary SKPs were passaged
into medium without drugs and the number (A and C) and size (B and D) of secondary spheres were quantified. n = at least three inde-
pendent experiments each and error bars indicate SEM. *p < 0.05, **p < 0.01, ***p < .001, one-way ANOVA with multiple comparison post
hoc tests except for (B), where pairwise comparisons of control versus alprostadil or TM were made with Student’s t test.
(E and F) mRNA from secondary SKP spheres generated as in (A–D) were analyzed on Affymetrix GeneChip Mouse Gene 2.0 ST arrays.
(E) Heatmap and hierarchical clustering of all the samples based on probesets that differed by p < 0.01 (unadjusted) regardless of the fold
change when comparing SKPs from vehicle-treated, injured skin versus alprostadil-treated injured skin. Three independent replicates of
SKPs from vehicle-treated injured skin (Con Inj), alprostadil- or TM-treated injured skin (Alp Inj or TM Inj), and vehicle-treated uninjured
skin (Con Uninj) were compared.
(legend continued on next page)
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shared (Figure 3I), suggesting mechanistic convergence
between alprostadil and TM.
Gene ontology (GO) enrichment analysis using the
GOstats bioconductor package (Falcon and Gentleman,
2007) showed that, consistent with the biological effects
of alprostadil and TM, genes associated with cell prolifera-
tion were significantly enriched (Figure 3J) for both drugs.
Of the genes that were associated with proliferation (Table
S8), 25 overlapped between TMand alprostadil, and a num-
ber encoded either growth factors (such as LIF, IL6, and
FGF10) or growth factor receptors (such as LIF and EGF
receptors). Intriguingly, of all the signaling pathways, GO
terms indicating positive regulation of the MAP kinase
pathway were most highly enriched for both drugs (Fig-
ure 3K; Table S9), suggesting that they might increase SKP
self-renewal by activating this pathway.
Alprostadil and TM Likely Regulate SKPs by
Stimulating a MEK-ERK Self-Renewal Pathway
On the basis of these findings, we askedwhether alprostadil
or TM activated the MEK-ERK pathway in cultured SKPs.
We cultured dissociated SKPs for 24 hr, added 100 nM al-
prostadil or TM for 10 min, and performed western blots
for phosphorylated, activated ERK1/2. SKPs grown in
FGF2 and EGF had basal levels of ERK1/2 phosphorylation
that were increased approximately 2-fold by treatment
with either drug (Figures 4A and 4B). In contrast, neither
drug increased the phosphorylated activated forms of
STAT3, GSK3beta, Akt1, or CREB (Figure 4C and S.N.,
F.D.M., and D.R.K., unpublished data).
We next asked whether MEK-ERK activity was important
for SKP self-renewal, using the highly selective MEK1/2 in-
hibitor trametinib (GSK1120212) (Gilmartin et al., 2011),
after first demonstrating that it inhibited basal ERK1/2
phosphorylation in cultured SKPs (Figure 4D). To ask about
self-renewal, we used the methylcellulose colony forma-
tion assay. Trametinib decreased both the number (Fig-
ure 4E) and size (Figure 4F) of clonal spheres grown in
FGF2 and EGF.MEK inhibition also decreased SKPs prolifer-
ation, as monitored by Ki67 immunostaining of SKP
spheres cultured for 48 hr with or without trametinib,(F) Venn diagram comparing the overlap of genes that differed by p <
(Control) versus TM- or alprostadil-treated injured skin.
(G–K) Three independent preparations of primary neonatal rat SKPs w
(Con), and mRNA was isolated and analyzed on an Affymetrix GeneCh
vehicle versus alprostadil- or TM-treated SKPs showing the average of t
(unadjusted) with a fold change of greater than 1.1. (H and I) Venn di
(unadjusted) (H) or the top 50 most significantly changed genes (I) fro
SKPs. The 23 overlapping genes in (I) are shown underneath. (J and K
were significantly different in the comparisons of vehicle (Ctrl) v
enrichment for categories involving cell proliferation (J) and the MAP
S4, S5, S6, S7, S8 and S9.
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morphology (Figures 4G and 4H).
Three lines of evidence indicated that MEK-ERK activity
was also important for drug-induced self-renewal. First,
trametinib suppressed the ability of alprostadil and TM to
increase ERK1/2 phosphorylation in SKPs cultured for
24 hr (Figure 4I). Second, in 7-day sphere assays, inhibition
of MEK with 100 nM trametinib robustly decreased sphere
number and neither drug could compensate for this
decrease (Figure 4J). Third, microarrays showed that trame-
tinib decreased, in part, the downstream gene expression
changes seenwhen SKPswere cultured in TM for 24 hr. Spe-
cifically, of the top 50 genes changed by TM treatment,
over half (29) had a reduced fold change when trametinib
was also included in the cultures (Figure 4K).DISCUSSION
The experiments presented here identify compounds that
promote SKP self-renewal and proliferation in culture,
and provide evidence that these compounds activate
dermal precursors in vivo to promote skin repair. They
also define the MEK-ERK pathway as a key self-renewal
pathway for SKPs, and suggest that molecules targeting
distinct cell surface receptors enhance self-renewal by
converging on this intracellular signaling pathway. These
data therefore provide support for the concept that phar-
macological activation of endogenous tissue stem cells pro-
vides a valid therapeutic approach (Miller and Kaplan,
2012).
How do alprostadil, TM, and SKP growth factors activate
the MEK-ERK pathway to enhance SKP proliferation and
self-renewal? FGF2 and EGF signal via receptor tyrosine ki-
nases expressed by SKPs, and are well-known activators of
the MEK-ERK pathway. Alprostadil (PGE1) binds to the
EP1–4 isoforms of the EP family of receptors (Breyer et al.,
2001), which are known to stimulate ERK1/2 (Yu et al.,
2008). TM binds peripheral mu and kappa-opioid receptors
(Kaneto et al., 1990), which also activate ERK1/2 (Gutstein
et al., 1997). Thus, three distinct cell surface cues converge0.01 (unadjusted) from pairwise comparisons of SKPs from vehicle
ere dissociated and cultured for 24 hr in alprostadil, TM, or vehicle
ip Rat Gene 2.0 ST array. (G) Heatmaps of pairwise comparisons of
he raw expression (log2) data for probesets that differed by p < 0.01
agrams comparing the overlap of all genes that differed by p < 0.01
m pairwise comparisons of vehicle versus TM- or alprostadil-treated
) Gene ontology (GO) enrichment analysis for gene categories that
ersus TM- or alprostadil-treated SKPs showing highly significant
kinase (MAPK) pathway (K). See also Figure S2 and Tables S1, S2, S3,
s
Figure 4. Signaling via the MEK-ERK Pathway Is Necessary for Basal and Drug-Induced SKPs Self-Renewal
(A–C) SKPs were treated with alprostadil (Alp), TM, or vehicle (Control) for 10 min, and lysates probed on western blots with anti-
phosphorylated ERK1/2 T202/Y204 (pERK) (A) or anti-phosphorylated STAT3 (C) and reprobed for total ERK1/2 or total STAT3. (B) shows
quantification by scanning densitometry of three experiments as in (A), where pERK was normalized to total ERK1/2.
(D) Western blot of SKPs treated with varying concentrations of trametinib (MEKi) or DMSO (Control) for 30 min, probed for pERK1/2 and
reprobed for total ERK1/2.
(E and F) Number (E) and size (F) of SKP spheres generated in clonal methylcellulose assays from secondary neonatal rat SKPs grown
14 days in 100 nM trametinib or DMSO.
(G and H) Secondary rat SKPs were cultured for 4 days, and 10 or 100 nM trametinib added for 2 more days. (G) shows spheres immu-
nostained for Ki67 (top) and counterstained with DAPI (bottom). (H) shows the percentage of Ki67-positive cells. Scale bar represents
100 mm.
(I) Western blot of SKPs treated with 100 nM trametinib for 30 min and coincidently stimulated with 100 nM alprostadil or TM for the final
10 min, probed for pERK1/2, and reprobed for total ERK1/2.
(J) Number of rat SKP spheres generated over 7 days in 100 nM alprostadil or TM with or without 100 nM trametinib.
(K) Heatmap comparing microarray data for three independent preparations of dissociated rat SKPs cultured for 24 hr in TM with or without
trametinib, focusing on 29 of the top 50 genes that were altered by TM relative to control (see Figure 3), and that were significantly
normalized by MEK inhibition. The heatmap shows the average of the raw expression (log2) data for probesets that differed by p < 0.01
(unadjusted). In all cases, results are pooled from at least three independent experiments.
Error bars indicate SEM, and **p < 0.01, ***p < 0.001, one-way ANOVA with multiple comparison post hoc tests, except (E and F), which
were analyzed by Student’s t test.
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on a single intracellular pathway to enhance SKP self-
renewal.
How do SKP self-renewal drugs promote skin repair? We
previously showed that SKPs arise from, and are similar to,
endogenous dermal precursors, and that transplantation
of either population led to dermal reconstitution, dermal
repair, and hair follicle morphogenesis (Biernaskie et al.,
2009). We therefore propose that alprostadil and TM
enhance skin repair by promoting proliferation and self-
renewal of endogenous dermal precursors. Support for this
idea comes from the data showing that SKPs isolated from
drug-treated regenerating skin displayed a long-term in-
crease in self-renewal. We suggest that alprostadil and TM
enhanced the self-renewal and numbers of dermal precur-
sors in vivo, and that this resulted in an increase in SKP
sphere formation in culture. Precedent for this idea comes
from studies where transient embryonic exposure to IL-6
ledtoanincrease inadult forebrainneuralprecursors invivo,
and a persistent increase in sphere formation when these
adult precursorswere cultured (Gallagher et al., 2013). How-
ever, while our findings suggest that activation of dermal
precursors underlies the enhanced skin repair, they do not
exclude the possibility that alprostadil and/or TM also regu-
late other endogenous cells to promote wound healing.
Chronic skin wounds are a major medical problem (Em-
ing et al., 2014), and there is a paucity of safe and effective
approaches for promoting wound healing. Our findings
suggest that targeting endogenous dermal precursors by re-
purposing of drugs already known to be safe in humans
provides a new therapeutic approach for this largely unmet
medical need.EXPERIMENTAL PROCEDURES
Animals
This study was approved by the Hospital for Sick Children Animal
Care Committee, in accordance with CCAC guidelines. Sprague-
Dawley rats were purchased from Charles River. Punch wounds
were performed on 9-month-old C57/Bl6 mice as described in
the Supplemental Experimental Procedures (Biernaskie et al.,
2009; Johnston et al., 2013). 100 ml of drugs or vehicle were applied
topically around the wound or on uninjured shaved skin daily for
7–9 days, as indicated.
Cell Cultures
Neonatal rat SKPs were cultured from dorsal skin as previously
described (Biernaskie et al., 2009; Fernandes et al., 2004) and in
the Supplemental Experimental Procedures. For human SKPs, ano-
nymized foreskin tissue from voluntary circumcisions was ob-
tained with approval of the Research Ethics Board of the Hospital
for Sick Children, and grown as described (Toma et al., 2005;
Krause et al., 2014) and in the Supplemental Experimental Proce-
dures. NIH 3T3 cells were grown as described in the Supplemental
Experimental Procedures.82 Stem Cell Reports j Vol. 6 j 74–84 j January 12, 2016 j ª2016 The AuthorDrug Composition and Reagents
Drugs were reconstituted in DMSO (Sigma) at 50 mM for culture
studies, and at 100 mM in propylene glycol-ethanol-water
(40%:20%:40%) for topical application. All drugs were obtained
from Sigma except latanoprost (Cayman Chemical) and trameti-
nib (MedChemexpress).
SKP Screens
Screens using alamarBlue were performed as previously described
(Smith et al., 2010) and in the Supplemental Experimental
Procedures.
Sphere Formation Assays
Unless otherwise indicated, secondary or tertiary rat or human SKP
sphereswere seeded at 3,000–5,000 cells/well in 96-well plates, and
compounds were added upon plating and at 3 days with fresh me-
dium. At 7 days, cells were fixed, nuclei were stained with Hoechst
33258, sphere numberswere countedmanually, and sizewas deter-
mined using Northern Eclipse software. For clonal sphere assays,
SKPs were plated at 2,500 cells/ml in medium containing 1.6%
methylcellulose and cultured for 14 days, as previously (Jinno
et al., 2010; Biernaskie et al., 2009), with compounds added on
days 1, 4, 8, and 12.
Tissue Preparation and Morphometric Analyses
Morphometric analyses were performed on paraffin-embedded
sections, as described previously (Johnston et al., 2013) and
in the Supplemental Experimental Procedures. Ki67-positive
cells or CD31-positive blood vessels were determined from five
representative 150-mm2 fields randomly distributed over the
leading edge of the regenerating dermis bordering the
new epithelium, using Northern Eclipse software (Empix). All
morphometric analyses were performed in a blinded manner.
Antibodies are described in the Supplemental Experimental
Procedures.
Western Blot Analysis
Secondary SKP spheres were dissociated and seeded at 106 cells/
well in 6-well plates (Costar), cultured for 24 hr, treated as indi-
cated, and analyzed on western blots as described (Naska et al.,
2010). Densitometry was performed after subtracting the back-
ground using ImageJ software. Antibodies are described in the Sup-
plemental Experimental Procedures.
Microarray Analysis
For microarrays of neonatal rat SKPs, secondary spheres were
dissociated, treated with 100 nM drugs for 24 hr. For in vivo
drug treatments, secondary SKP spheres were generated from
drug-treated murine skin in medium without additional drugs.
In both cases, RNA was isolated using the RiboPure Kit (Ambion
by Life Technologies) and quality assessed by an Agilent
BioAnalyzer. cDNA was generated with the Ambion Whole Tran-
script Expression Kit (Applied Biosystems) and was hybridized to
the Affymetrix GeneChip Mouse Gene 2.0 ST or Rat Gene 2.0 ST
arrays. The hybridized microarray image was scanned with the
GeneChip Scanner 3000 7G (Affymetrix). Raw probe intensitys
values were background corrected, normalized with quantile
normalization, transformed into the log2 scale, and summarized
into probesets with the Robust Multichip Analysis algorithm us-
ing the Oligo bioconductor package in R (Carvalho and Irizarry,
2010). For calculation of differential gene expression, the limma
bioconductor package was used to calculate Bayesian statistics. In
these analyses, any annotated gene with an expression change of
p < 0.01 was considered statistically significant. For the hierarchi-
cal clustering and heatmap analysis, all the genes with p < 0.01
when comparing the injured skin and the alprostadil groups
were used to perform the cluster and heatmap analysis on all
groups using the heatmap.2 function of the gplots package
in R. In this case, the complete linkage method of a Euclidian dis-
tance matrix was used to perform the cluster analysis. For acutely
treated rat SKPs, heatmaps were produced by averaging log2
expression data for the three replicates for the appropriate groups
and these data were displayed using the heatmap.2 function as
described above. GO analysis was performed using the GOstats
bioconductor package in R. The gene universe in this analysis
was all of the mapped keys in the org.Mm.egGO and
org.Ra.egGO databases for the Mouse Gene 2.0 ST and Rat
Gene 2.0 ST arrays, respectively, while the differentially ex-
pressed genes (computed as described above) served as the
enrichment samples. The threshold p value in the GO analysis
was set at p < 0.001.Statistical Analysis
Except for microarrays, data were expressed as the mean plus or
minus the SEM and were tested for statistical significance with
one-way ANOVA plus Dunnett’s, Newman-Keuls’, or Tukey’s post
hoc multiple comparison tests, unless otherwise indicated. All
studies were performed with at least three independent biological
replicates.ACCESSION NUMBERS
Microarray data have been submitted to the NCBI GEO database
under the accession number GEO: GSE73329.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, two figures, and nine tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
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